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Abstract
Background: The role of HLA-DR antigens in the clinicopathological features of autoimmune hepatitis (AIH) is not clearly
understood. We examined the implications of HLA-DR antigens in Japanese AIH, including the effect of HLA-DR4 on the
age and pattern of AIH onset, clinicopathological features, and treatment efficacy.
Methods: A total of 132 AIH patients consecutively diagnosed and treated in 2000–2014 at 2 major hepatology centers
of eastern Tokyo district were the subjects of this study. The frequency of HLA-DR phenotypes was compared with that in
the healthy Japanese population. AIH patients were divided into HLA-DR4–positive or HLA-DR4–negative groups and
further sub-classified into elderly and young-to-middle-aged groups, and differences in clinical and histological features
were examined. Clinical features associated with the response to immunosuppressive therapy were also determined.
Results: The frequency of the HLA-DR4 phenotype was significantly higher in AIH than in control subjects
(59.7 % vs. 41.8 %, P < 0.001), and the relative risk was 2.14 (95 % CI; 1.51–3.04). HLA-DR4–positive AIH patients were
younger than HLA-DR4–negative patients (P = 0.034). Serum IgG and IgM levels were higher (P < 0.001 and P = 0.007,
respectively) in HLA-DR4–positive patients. These differences were more prominent in elderly AIH patients. However,
there was no difference in IgG and IgM levels between HLA-DR4–positive and HLA-DR4–negative patients of the
young-to-middle-aged group. There were no differences in the histological features. In patients with refractory to
immunosuppressive therapy, higher total bilirubin, longer prothrombin time, lower serum albumin, and lower platelet
count were found. Imaging revealed splenomegaly to be more frequent in refractory patients than in non-refractory
patients (60.0 % vs. 30.8 %, P = 0.038). HLA-DR phenotype distribution was similar regardless of response to
immunosuppressive therapy.
Conclusions: HLA-DR4 was the only DR antigen significantly associated with Japanese AIH. The clinical features
of HLA-DR4–positive AIH differed between elderly patients and young-to-middle-aged patients. Treatment
response depended on the severity of liver dysfunction but not on HLA-DR antigens.
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Background
Autoimmune hepatitis (AIH) is a rare inflammatory liver
disease, with prevalence rates of 5–20 per 100,000 in
Europe and North America [1, 2]. Although the etiology
of AIH remains unknown, AIH predominantly affects
women and is characterized by a marked elevation of
serum immunoglobulin levels and the emergence of
autoantibodies [3, 4]. The diagnosis relies on a
combination of indicative features of AIH and exclusion
of other liver diseases. To confirm the diagnosis of AIH,
a set of diagnostic criteria, the International Diagnostic
Criteria for the Diagnosis of AIH, is generally applied
[5]. AIH is classified as type 1 or type 2 according to the
type of autoantibodies [6–8]. In Japan, most cases of
AIH have been found to be of type 1 [9].
As regards the immunogenetic background of AIH,
HLA-DR3 (recently split into DR17 and DR18) and
HLA-DR4 are associated with type 1 AIH [10]. In Japan,
HLA-DR4 is frequently found in AIH patients, as has
been shown in European or North American Caucasoid
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patients. However, HLA-DR3–positive AIH is quite rare,
because the prevalence of DR3 is extremely rare in the
normal Japanese population [9].
In a report on North American patients, the clinical
features of HLA-DR4–positive AIH differed from those
of HLA-DR4–negative patients [11]. In addition, the
clinical features of AIH in elderly patients differed from
those of younger patients [12–14]. Recently, a lower fre-
quency of HLA-DR4 and a higher frequency of histolog-
ically acute hepatitis were reported in adolescent and
early adulthood AIH [14]. Moreover, elderly AIH has
been increasing in Japan. However, the role of the HLA-
DR antigen on the clinical features, including age at
onset of AIH and treatment efficacy, has not been exten-
sively studied.
In the present study, we thoroughly examined the role
of HLA-DR antigens in Japanese AIH, including how
HLA-DR4 influences the age of AIH onset and its clin-
ical features. The association of HLA-DR antigens with
the treatment efficacy was also examined.
Methods
Study population and study design
A total of 132 patients who had been consecutively diag-
nosed with AIH, treated, and examined for the HLA-DR
antigen at Tokyo Metropolitan Bokutoh Hospital and
the Jikei University School of Medicine Katsushika
Medical Center (2 of the major hepatology centers in
eastern Tokyo district) from the beginning of 2000 till
May 2014 were the subjects of this study. AIH diagnosis
was based on the Diagnostic Criteria of the International
Autoimmune Hepatitis Group (IAHG) [2], which defines
AIH on the basis of definite or empirical judgment by
experienced hepatologists after ruling out other liver dis-
ease such as primary biliary cirrhosis, drug-induced liver
disease, hemochromatosis, primary sclerosing cholan-
gitis, Wilson’s disease, α1-antitrypsin deficiency, active
cytomegalovirus infection, active Epstein–Barr virus in-
fection, non-alcoholic steatohepatitis, congestive liver in-
jury, and ischemia.
The medical records of the subjects at the time of
diagnosis were collected and analyzed retrospectively. In
addition, the clinical course of all AIH patients was sur-
veyed. The collected laboratory data included aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), total bilirubin (TB), albumin
(Alb), platelet count (PLT), prothrombin time (PT), im-
munoglobulin G (IgG), immunoglobulin M (IgM), anti-
nuclear antibodies (ANA), anti-mitochondrial antibodies
(AMA), HCV- and HBV-related viral markers, drug his-
tory, average alcohol intake, liver histology, other con-
comitant autoimmune diseases, and other defined
autoantibodies. ANA and AMA were detected and ti-
trated by standard indirect immunofluorescence. For
imaging, computed tomography and/or ultrasonography
were performed for all but 4 patients, and the presence or
absence of splenomegaly was evaluated by radiologists.
HLA-DR antigens were assayed in all patients by PCR-
based reverse sequence specific oligonucleotide typing
(SRL or BML, Tokyo, Japan). Pre-treatment AIH score
was calculated in every patient. Then, the frequencies of
HLA-DR phenotypes were assessed, and the importance
of HLA-DR4 in clinical features in elderly or younger AIH
patients was analyzed. The effect of HLA-DR antigens
on response to immunosuppressive therapy was also
examined.
The protocol of this study was approved by the Ethical
committee of Tokyo Metropolitan Bokutoh Hospital and
the Ethical committee of the Jikei University School of
Medicine. Information of the protocol of this study was
explained to the participants, and verbal informed con-
sent was obtained from all patients. This study complied
with the standards of the 2008 Declaration of Helsinki
and current ethical guidelines.
Sub-grouping of AIH patients according to HLA-DR4
AIH patients were divided into HLA-DR4–positive and
HLA-DR4–negative groups. They were further sub-
classified into an elderly group (diagnosed at ≥65 years;
49 patients) and a young-to-middle-aged group (diag-
nosed at ≤55 years; 49 patients). In each age group,
the differences in the clinical features between HLA-
DR4 − positive and HLA-DR4 − negative patients were
examined.
Histological examination
Sufficient liver tissue (longer than 2 cm, obtained by 16-
or 18-gauge needles) was obtained by percutaneous liver
biopsy before starting therapy in 116 out of 132 AIH pa-
tients. Among the remaining 16 patients, consent for
liver biopsy could not be obtained in 2; immunosuppres-
sive drugs had already been taken based on the clinical
diagnosis of AIH in 3; and percutaneous liver biopsy was
contraindicated because of severe liver damage in 8 pa-
tients. Biopsy specimens could not be obtained in 2 pa-
tients, and sufficient length of biopsy specimen was not
achieved in 1 patient. The biopsy samples were stained
by hematoxylin/eosin and Masson’s trichrome or Azan.
The pathological features of AIH were determined col-
lectively by a single pathologist (AS) blinded to clinical
information. Pathological scoring of AIH based on the
degree of interface hepatitis, predominance of lympho-
plasmacytic infiltrate, and presence of rosetting of liver
cells was performed according to the diagnostic criteria
of the IAHG [2]. In addition, histological staging was
assessed based on the Metavir score (F0: no fibrosis, F1:
portal fibrosis without septa, F2: portal fibrosis with few
septa, F3: numerous septa without cirrhosis and F4:
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cirrhosis). F0-F2 was considered non-to-mild fibrosis,
while F3-F4 was considered advanced fibrosis.
Criteria of acute or chronic AIH
Patients with acute liver dysfunction (serum ALT levels
higher than 10 times of the upper normal limit) or with
acute liver-related symptoms (fatigue, jaundice, and ap-
petite loss) without evidence of liver dysfunction in the
past (more than 6 months before diagnosis) was defined
as acute-onset AIH, while the others were defined as
chronic onset AIH. This classification was based on a re-
port by Miyake et al. [15].
Distribution of HLA-DR antigens in AIH
HLA-DR phenotype frequencies in AIH were deter-
mined and compared with those in a large-scale popula-
tion study on healthy Japanese people by the HLA
Laboratory, Kyoto, Japan [16].
Treatment of AIH patients
Of 132 AIH patients, 121 (92 %) were treated by pred-
nisolone alone or in combination with an immunomod-
ulator (azathioprine, cyclosporine, or tacrolimus). The
remaining 11 patients were treated with ursodeoxycholic
acid alone because of mild inflammatory activity [17].
Prednisolone alone and in combination with azathio-
prine was defined as the “standard therapy.” The initial
doses of prednisolone were 0.2–1.0 mg/kg except for 2
patients for whom methylprednisolone pulse therapy
(1000 mg/day) was selected. Prednisolone doses were
gradually decreased to maintenance doses of 10 mg/day
or less. Azathioprine doses were adjusted to 0.5–1 mg/kg
and maintained [2]. The other immunomodulators were
used for patients who were resistant to the standard ther-
apy or could not continue azathioprine use because of ad-
verse reaction [2, 18, 19].
Statistical analysis
Results are expressed as number (%) or median
(minimum–maximum). Fisher’s exact test or chi-
square test was used to analyze differences in categorical
data. The Mann–Whitney U-test was used to analyze
differences between continuous variables. Statistical sig-
nificance was determined by a two-tailed test and P-values
of ≤0.05 were considered significant. All statistical ana-
lyses were carried out using STATISTICA for Windows
version 6 (StatSoft, Tulsa, OK, USA).
Results
Frequency of HLA-DR phenotypes in AIH patients
The frequency of the HLA-DR4 phenotype was sig-
nificantly higher in AIH than in control individuals
(59.7 % vs. 41.8 %, P < 0.001). The relative risk (RR)
of HLA-DR4 was 2.14 (95 % CI; 1.51–3.04).
Among the other HLA-DR antigens, HLA-DR14
tended to be more frequent and HLA-DR11, HLA-
DR12, and HLA-DR15 less frequent in AIH compared
with control subjects, although the differences were not
statistically significant (Table 1).
Comparison of clinical features between HLA-DR4–positive
and HLA-DR4–negative AIH
HLA-DR4–positive AIH patients were younger than
HLA-DR4–negative patients. Serum IgG and IgM levels
were higher in HLA-DR4–positive patients than in
HLA-DR4–negative patients. Splenomegaly was less fre-
quently seen in HLA-DR4–positive AIH, but the differ-
ence was not statistically significant. Otherwise,
differences were not observed in the remaining demo-
graphic or laboratory data, including AST, ALT, ALP,
ANA titers, fibrosis stage or pretreatment AIH scores
(Table 2).
Differences in the effect of HLA-DR4 between
young-to-middle-aged and elderly AIH patients
According to the age distribution of HLA-DR4–positive
and HLA-DR4–negative AIH patients, AIH developed
most frequently in individuals in their 50s in HLA-
DR4–positive patients and in their 70s in HLA-DR4–
negative patients. HLA-DR4–positive AIH was more fre-
quent than HLA-DR4–negative AIH in the age group of
20–59 years. HLA-DR4–negative AIH, however, was
more frequent than HLA-DR4–positive AIH in individ-
uals in their 70s (Fig. 1)
In AIH patients diagnosed at age 65 and above (elderly
AIH), 22 patients had HLA-DR4, while 27 did not. Both
serum IgG and IgM levels were higher in elderly HLA-
DR4–positive AIH patients than in HLA-DR4–negative
patients. These differences between HLA-DR4–positive
and HLA-DR4–negative elderly AIH patients were
greater than those shown with the whole population.
Moreover, pretreatment AIH scores (including histo-
logical score) were significantly higher in the HLA-
DR4–positive group than in the HLA-DR4–negative
group. Advanced fibrosis tended to be more frequent in
HLA-DR4–positive elderly AIH patients (Table 3). With
regard to the HLA-DR distribution in elderly AIH pa-
tients, the HLA-DR4 phenotype comprised only 44.9 %,
and none of HLA-DR antigens were associated with eld-
erly AIH.
In AIH patients younger than 55 years (young-to-
middle-aged AIH), 34 of 49 (63.8 %) patients had
HLA-DR4. The clinicopathological features between
HLA-DR4–positive and HLA-DR4–negative AIH were
similar except for splenomegaly, which was less fre-
quently found in HLA-DR4–positive patients. In con-
trast to elderly AIH, serum levels of IgG and IgM or
pretreatment AIH scores (including histological score)
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Table 1 Frequency of HLA–DR phenotypes in Japanese patients with autoimmune hepatitis
HLA–DR phenotype Autoimmune hepatitis (n = 132) Control subjects (n = 31973) P–value Odds ratio (95 % Cl)
1 16 (11.9 %) 3645 (11.4 %) 0.795 1.07 (0.63–1.81)
4 80 (59.7 %) 13365 (41.8 %) <0.001 2.14 (1.51–3.04)
7 1 (0.7 %) 239 (0.75 %) 0.622 1.01 (0.14–7.28)
8 38 (28.4 %) 7513 (23.5 %) 0.153 1.32 (0.90–1.92)
9 27 (20.1 %) 8505 (26.6 %) 0.111 0.71 (0.46–1.08)
11 2 (1.5 %) 1644 (5.143 %) 0.092 0.28 (0.07–1.15)
12 8 (6.0 %) 3485 (10.9 %) 0.100 0.53 (0.26–1.08)
13 14 (10.4 %) 4029 (12.6 %) 0.577 0.82 (0.44–1.43)
14 25 (18.7 %) 4348 (13.6 %) 0.074 1.48 (0.96–2.30)
15 34 (25.4 %) 10647 (33.3 %) 0.066 0.69 (0.47–1.03)
16 3 (2.2 %) 575 (1.8 %) 0.935 1.27 (0.40–4.00)
17 1 (0.7 %) 88 (0.28 %) 0.824 2.77 (0.38–20.0)
6 *1 3 (2.2 %) –
*1 Defined as DR6 before DR6 was further split into DR13 and DR14
Bold-faced type shows statistically significant difference
Table 2 Clinical features of HLA–DR4–positiveand HLA–DR4–negativeautoimmune hepatitis
HLA–DR4–positive AIH (n = 78) HLA-DR4-negative AIH (n = 54) P–value
Discrete traits N (%) N (%)
Sex 0.524
Male 8 (10.3) 3 (5.6)
Female 70 (89.7) 51 (94.4)
Pattern of disease onset Acute onset 27 (34.6) 20 (37.0) 0.854
Other autoimmune diseases 16 (20.5) 7 (13.0) 0.352
Death from liver disease–related causes 3 (3.8) 5 (9.3) 0.271
ANA positivity 71 (91.0) 44 (81.5) 0.121
ANA (<40/40/80/>80) 7/9/18/44 10/8/10/26 0.435
AMA positivity 9 (11.5) 4 (7.4) 0.558
Splenomegaly 21 (27.6) 23 (44.2) 0.090
Fibrosis stage (F0–F2/F3–F4) 38/31 31/16 0.255
Continuous traits Median (Min–Max) Median (Min–Max) P–value
Age (years) 56 (15–86) 65 (9–88) 0.034
Total bilirubin (mg/dl) 1.1 (0.4–20.4) 1.1 (0.5–33.2) 0.957
Aspartate aminotransferase (U/L) 203.5 (21–2738) 254.5 (20–1536) 0.930
Alanine aminotransferase (U/L) 270 (15–2325) 284 (16–2016) 0.779
Alkaline phosphatase (U/L) 448.5 (213–1145) 459 (131–1463) 0.860
Gamma–glutamyl transpeptidase (IU/L) 145.5(26–1404) 147.5 (20–679) 0.842
Prothrombin time (%) 86 (29–130) 82 (3–130) 0.251
Albumin (g/dL) 3.7 (1.9–4.7) 3.8 (2.2–4.7) 0.239
Platelets (x 104/nL) 17.7 (8.9–39.6) 17.55 (6.8–31.5) 0.185
Immunoglobulin G (mg/dL) 2582.5 (938–6750) 2074.5 (945–4961) <0.001
Immunoglobulin M (mg/dL) 181 (62–1720) 115 (47–888) 0.007
AIH score (except for histology score) 14 (6–18) 13 (7–17) 0.117
AIH score (including histology score) 18 (9–22) 17 (8–22) 0.450
Bold-faced type shows statistically significant difference











Fig. 1 Age distribution of HLA-DR4–positive and DR4-negative autoimmune hepatitis (AIH) patients. Open bars show the number of DR4-positive
AIH patients. Dotted bars show the number of DR4-negative AIH patients
Table 3 Clinical features of HLA-DR4-positiveand HLA-DR4-negativeautoimmune hepatitis in elderly patients (>65 years old)
HLA-DR4-positive AlH (n = 22) HLA-DR4-negative AIH (n = 27) P-value
Discrete traits N (%) N (%)
Sex 0.084
Male 3 (13.6) 0 (0)
Female 19 (86.4) 27 (100)
Pattern of disease onset Acute onset 4 (18.2) 11 (40.7) 0.123
Other autoimmune diseases 4 (18.2) 2 (7.4) 0.388
Death from liver disease-related causes 2 (9.10 3 (11.1) 1.000
ANA positivity 22 (100) 24 (88.9) 0.242
ANA (<40/40/80/<80) 0/1/6/15 3/5/6/13 0.065
AMA positivity 5 (22.7) 2 (7.4) 0.219
Splenomegaly 9 (40.9) 8 (30.8) 0.548
Fibrosis stage (F0-F2/F3-F4) 6/11 16/7 0.053
Continuous traits Median (Min-Max) Median (Min-Max) P-value
Age (years) 72 (65–86) 73 (66–88) 0.657
Total bilirubin (mg/dL) 1.1 (0.5–19.0) 1.1 (0.5–33.2) 0.976
Aspartate aminotransferase (U/L) 188 (58–1177) 290 (20–641) 0.376
Alanine aminotransferase (U/L) 191 (62–1208) 284 (16–714) 0.330
Alkaline phosphatase (U/L) 441.5 (239–1145) 443 (170–793) 0.802
Gamma-glutamyl transpeptidase (IU/L) 130.5 (47–466) 203 (20–587) 0.287
Prothrombin time (%) 80.5 (30–104.8) 82 (49–114.4) 0.481
Albumin (g/dL) 3.5 (2.2–4.5) 3.8 (2.2–4.6) 0.190
Platelets (x 104/pL) 14.85 (9.6–27.7) 15.7 (8.0–28.8) 0.920
Immunoglobulin G (mg/dL) 2724.5 (1758–5495) 2030 (1243–3157) <0.0001
Immunoglobulin M (mg/dL) 215 (62–1330) 98 (47–396) 0.003
AIH score (except for histology score) 14 (7–17) 13 (7–16) 0.053
AIH score (including histology score) 19 (12–22) 17 (8–21) 0.037
Bold-faced type shows statistically significant difference
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did not differ between HLA-DR4–positive and HLA-
DR4–negative patients. Moreover, the fibrosis stage
was similar between HLA-DR4–positive and HLA-DR4–
negative AIH (Table 4).
Treatment outcome and HLA-DR antigens
Normalization of serum ALT/AST level was accom-
plished within 6 months in 106 out of 121 patients by
the standard therapy. In the remaining 15 patients, 8 de-
veloped liver failure and/or died due to liver-related
complications, and 7 went into remission by additional
dosage of cyclosporine or tacrolimus.
The acute-onset AIH was more frequent in the pa-
tients in whom remission was induced by the standard
therapy within 6 months (non-refractory group) than in
the patients resistant to the standard therapy (refractory
group). Splenomegaly was less frequently found in the
non-refractory group than in the refractory group. TB
was lower, PT was longer, and Alb and PLT were higher
in the non-refractory group. Moreover, the serum ALP
level was lower in the non-refractory group. The occur-
rence of advanced liver fibrosis was not different, but
the number of patients who did not undergo liver biopsy
was higher in the refractory group than in the non-
refractory group (40.0 % vs. 8.5 %, P = 0.003). In the re-
fractory group, the 6 patients who did not undergo liver
biopsy were those for whom liver biopsy was contraindi-
cated because of severe hepatic deterioration (Table 5).
HLA-DR phenotype distribution was similar between
the non-refractory and refractory groups.
Discussion
HLA-DR4 is the most important immunogenetic factor
responsible for type 1 AIH in Japan [20]. However, the
frequency of HLA-DR4 in other countries ranges widely,
from 3 % to 59 % [21–25]. In a study of Italian and
Table 4 Clinical features of HLA-DR4-positiveand HLA-DR4-negativeautoimmune hepatitis in young-to middle-aged patients
(<55 years old)
HLA-DR4-positive AIH (n = 34) HLA-DR4-negative AIH (n = 15) P-value
Discrete traits N (%) N (%)
Sex 1.000
Male 5 (14.7) 2 (13.3)
Female 29 (85.3) 13 (86.7)
Pattern of disease onset Acute onset 17 (50.0) 7 (46.7) 1.000
Other autoimmune diseases 7 (20.6) 4 (26.7) 0.717
Death from liver disease-related causes 1 (2.9) 0 (0) 1.000
ANA positivity 28 (82.4) 10 (66.7) 0.275
ANA (<40/40/80/>80) 7/5/9/13 5/2/2/6 0.642
AMA positivity 4 (11.8) 1 (6.7) 1.000
Splenomegaly 6 (18.8) 10 (71.4) 0.002
Fibrosis stage (F0-F2/F3-F4) 23/8 8/5 0.478
Continuous traits Median (Min-Max) Median (Min-Max) P-value
Age (years) 46.5 (15–54) 36 (9–54) 0.178
Total bilirubin (mg/dL) 1.1 (0.4–30.4) 1.1 (0.6–18.6) 0.965
Aspartate aminotransferase (U/L) 313.5 (21–2314) 213 (42–1536) 0.957
Alanine aminotransferase (U/L) 499.5 (15–2207) 252 (39–2016) 0.983
Alkaline phosphatase (U/L) 477 (245–732) 491 (184–1463) 0.357
Gamma-glutamyl transpeptidase (IU/L) 181 (26–1404) 166 (23–679) 0.558
Prothrombin time (%) 94 (29–130) 85 (47–130) 0.389
Albumin (g/dL) 4.0 (2.2–4.7) 4.1 (2.9–4.7) 0.267
Platelets (x 104/pL) 21.65 (9.7–39.6) 18.0 (8.5–31.5) 0.175
Immunoglobulin G (mg/dL) 2116.5 (938–6750) 2305 (945–4961) 0.374
Immunoglobulin M (mg/dL) 179.5 (65–890) 231 (59–888) 0.428
AIH score (except for histology score) 12 (6–16) 13 (8–17) 0.197
AIH score (including histology score) 16 (9–21) 17 (9–22) 0.112
Bold-faced type shows statistically significant difference
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North American type 1 AIH, HLA-DR4 was found to be
less frequent in both Italian type 1 AIH and in control
Italian individuals compared with North American
counterparts [26]. Although HLA-DR4 is less frequent
in Italy, the frequency of HLA-DR4 in the control popu-
lation of Italy is also less than that of North American
counterparts. Although HLA-DR4 was not associated
with type1 AIH in Italy, the RR of HLA-DR4 for type 1
AIH in Italy (1.51) and North America (1.46) is quite
similar. Therefore, the variation in the frequency of
HLA-DR4 in type 1 AIH in different countries may
partly depend on the variation in the frequency of HLA-
DR4 in the background populations, and hence there is
no global consensus on the association of HLA-DR4 and
type 1 AIH.
A study on Japanese type 1 AIH revealed a very high oc-
currence of HLA-DR4 (>80 %) [27], warranting an exten-
sive re-assessment of the distribution of HLA-DR antigens
in Japanese AIH. Therefore, in this study, we evaluated
the significance of HLA-DR antigens in Japanese type 1
AIH patients. We found that HLA-DR4 alone was signifi-
cantly associated with Japanese type 1 AIH, but the fre-
quency was as low as 59.7 %. Meanwhile, HLA-DR4 is the
most frequent DR antigen (41.7 %) in the normal Japanese
population [16]. The RR of HLA-DR4 for type 1 AIH is
2.14, much higher than that for the Italian/North
American-type 1 AIH. Other HLA-DR antigens, including
HLA-DR13 and HLA-DR3 (DR17 or DR18) [28–31], were
not associated with AIH in our study population.
We next examined the role of HLA-DR4 on the clinical
features of type 1 AIH. HLA-DR4–positive AIH patients
were young and had hypergammaglobulinemia without
decreases in albumin levels or platelet count. Marked
hypergammaglobulinemia might be a common feature of
HLA-DR4–positive AIH in Japan [32]. According to age
distribution, about 70 % of AIH patients who were <30 years
Table 5 Clinical features of refractory and non-refractory groups
Non-refractory group (n = 106) Refractory group (n = 15) P-value
Discrete traits N (%) N (%)
Sex 0.356
Male 11 (10.4) 0 (0)
Female 95 (89.6) 15 (100)
Pattern of disease onset 45 (42.5) 2 (13.3) 0.045
Acute onset
Other autoimmune diseases 19 (17.9) 3 (20.0) 0.735
Death from liver disease-related causes 0 (0) 8 (53.3) <0.001
ANA positivity 92 (86.8) 13 (86.7) 1.000
ANA (<40/40/80/>80) 14/15/18/59 2/2/6/5 0.274
AMA positivity 13 (12.3) 0 (0) 0.366
Splenomegaly 32 (30.8) 9 (60.0) 0.038
Fibrosis stage (F0-F2/F3-F4) 55/42 5/4 1.000
Continuous traits Median (Min-Max) Median (Min-Max) P-value
Age (years) 57 (9–87) 64 (46–85) 0.167
Total bilirubin (mg/dL) 1.1 (0.4–30.4) 5.1 (0.8–33.2) 0.001
Aspartate aminotransferase (U/L) 248 (21–2738) 133 (46–1130) 0.229
Alanine aminotransferase (U/L) 310 (15–2325) 284 (30–741) 0.429
Alkaline phosphatase (U/L) 456 (131–1463) 564 (420–830) 0.007
Gamma-glutamyl transpeptidase (IU/L) 161 (26–679) 192 (48–1404) 0.532
Prothrombin time (%) 86 (29–130) 73 (43–109.1) 0.002
Albumin (g/dL) 3.8 (1.9–4.7) 3.2 (2.7–4.0) 0.004
Platelets (x 104/μL) 18.0 (8.9–39.6) 11.1 (6.8–36.8) 0.016
Immunoglobulin G (mg/dL) 2536 (938–6750) 2163(1654–5495) 0.514
Immunoglobulin M (mg/dL) 135.5 (47–1720) 172.5 (52–321) 0.618
AIH score (except for histology score) 14 (6–18) 13 (9–16) 0.748
AIH score (including histology score) 18 (8–22) 17 (9–21) 0.284
Bold-faced type shows statistically significant difference
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old were reported to be HLA-DR4– negative [32]. In our
patients, although the number of patients younger than
30 years old was relatively small, a tendency of decreasing
HLA-DR4 in teens and children was observed.
Interestingly, the incidence of HLA-DR4 differed be-
tween elderly and young-to-middle-aged patients. The
rate of HLA-DR4 in elderly patients was equal to that in
normal subjects. Therefore, HLA-DR4 is not necessarily
a risk factor contributing to the onset of AIH in elderly
individuals. However, in North America, the frequency
of DR4-positive AIH has been increasing in elderly pa-
tients, with a decline of DR3-positive AIH [12]. Mean-
while, in Japan, a higher frequency of advanced fibrosis
without a change in HLA-DR status has been reported
in elderly AIH patients [14]. In our study, the increase in
advanced fibrosis in elderly AIH patients was limited to
HLA-DR4 patients.
A critical difference between the present study and the
earlier one might be the high proportion of elderly AIH
patients in our study. Only 20 % of the patients were
elderly in the past study, while 34.1 % of the patients in
the current study were elderly. This can be attributed to
the increase in older population in Japan and recent pro-
gress in the proper diagnosis of AIH onset in the elderly.
In addition, when the results were compared with those
of Caucasian type 1 AIH, HLA-DR3–positive AIH was
negligible in the Japanese population.
HLA-DR4–positive elderly AIH patients exhibited
prominent hyperglobulinemia, which is one of the char-
acteristic features of typical AIH. In contrast, HLA-
DR4–negative elderly AIH patients may exhibit atypical
clinical results. Therefore, it is necessary to diagnose
HLA-DR4–negative elderly AIH patients carefully.
In young-to-middle-aged AIH patients, the rate of
HLA-DR4 was higher. The clinical characteristics were
not different between HLA-DR4–positive and HLA-
DR4–negative AIH. However, the number of AIH pa-
tients younger than 30 years was only 7 in our study.
Therefore, precise characterization of AIH in young
adults and/or children requires further research. For
children or young adults, careful diagnosis of AIH by an
experienced hepatologist is essential because differen-
tial diagnosis from other causes of liver damage, in-
cluding chronic active Epstein–Barr virus infection, is
difficult [33].
Finally, we examined the contribution of the HLA-DR
antigen to the response to immunosuppressive therapy.
Association of HLA-DR14 with a favorable response to
corticosteroid therapy [34], better treatment response of
HLA-DR4 than DR3 [11], lower occurrence of relapse
after drug withdrawal and higher frequency of sustained
remission in HLA-DR13 [30] have been reported. How-
ever, we did not find any differences in HLA-DR be-
tween refractory AIH and non-refractory AIH.
Patients with refractory AIH had severe deterioration
of liver function. Therefore, we assumed that treatment
efficacy was largely influenced by the functional deterior-
ation of the liver at the time of starting therapy. Thus,
proper diagnosis and therapy without delay are key fac-
tors for the successful treatment of AIH. Meanwhile, the
effect of HLA-DR on treatment efficacy may be negli-
gible; however, this cannot be conclusive because of the
limited patient number in our study.
Conclusion
The HLA-DR4 antigen alone was associated with Japa-
nese AIH. No other predisposing HLA-DR antigen was
recognized in this study. The impact of HLA-DR4 on
the features of AIH differed between elderly patients and
younger patients. Treatment response was associated
with the severity of liver disease but not with HLA-DR
antigen. AIH refractory to immunosuppressive therapy
was diagnosed in cases of severe liver dysfunction. Early
recognition, proper diagnosis, and immediate start of
immunosuppressive therapy are essential for favorable
treatment outcome.
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